Identification

Name
LFA703
Accession Number
DB03932  (EXPT00387)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 603.7881
Monoisotopic: 603.355988305
Chemical Formula
C37H49NO6
InChI Key
WPVRNXUYVXQXPY-YFAYRSKXSA-N
InChI
InChI=1S/C37H49NO6/c1-6-23(3)37(42)44-34-16-22(2)15-27-9-7-24(4)30(36(27)34)13-11-28-18-29(40)19-35(41)38(28)20-25-8-12-31-26(17-25)10-14-33(43-5)32(31)21-39/h7-10,12,14-15,17,22-24,28-30,34,36,39-40H,6,11,13,16,18-21H2,1-5H3/t22-,23-,24-,28-,29+,30-,34-,36-/m0/s1
IUPAC Name
(1S,3R,7S,8S,8aR)-8-{2-[(2S,4R)-4-hydroxy-1-{[5-(hydroxymethyl)-6-methoxynaphthalen-2-yl]methyl}-6-oxopiperidin-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
SMILES
[H][[email protected]](C)(CC)C(=O)O[[email protected]@]1([H])C[[email protected]@]([H])(C)C=C2C=C[[email protected]]([H])(C)[[email protected]]([H])(CC[[email protected]@]3([H])C[[email protected]@]([H])(O)CC(=O)N3CC3=CC4=C(C=C3)C(CO)=C(OC)C=C4)[[email protected]@]12[H]

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UIntegrin alpha-LNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
449169
PubChem Substance
46504607
ChemSpider
395776
HET
AAY
PDB Entries
1xdd

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00152 mg/mLALOGPS
logP5.51ALOGPS
logP5.19ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)14.62ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area96.3 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity174.37 m3·mol-1ChemAxon
Polarizability68.05 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8102
Blood Brain Barrier+0.5485
Caco-2 permeable-0.5432
P-glycoprotein substrateSubstrate0.8663
P-glycoprotein inhibitor INon-inhibitor0.6283
P-glycoprotein inhibitor IIInhibitor0.5377
Renal organic cation transporterNon-inhibitor0.6871
CYP450 2C9 substrateNon-substrate0.851
CYP450 2D6 substrateNon-substrate0.8161
CYP450 3A4 substrateSubstrate0.7615
CYP450 1A2 substrateNon-inhibitor0.7023
CYP450 2C9 inhibitorNon-inhibitor0.8567
CYP450 2D6 inhibitorNon-inhibitor0.8536
CYP450 2C19 inhibitorNon-inhibitor0.7819
CYP450 3A4 inhibitorInhibitor0.6508
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7378
Ames testNon AMES toxic0.6601
CarcinogenicityNon-carcinogens0.9021
BiodegradationNot ready biodegradable0.5732
Rat acute toxicity2.7841 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8512
hERG inhibition (predictor II)Inhibitor0.5889
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Alkaloids and derivatives / Anisoles / Piperidinones / Alkyl aryl ethers / Fatty acid esters / Delta lactams / Tertiary carboxylic acid amides / Secondary alcohols / Carboxylic acid esters / Azacyclic compounds
show 8 more
Substituents
Naphthalene / Alkaloid or derivatives / Anisole / Alkyl aryl ether / Delta-lactam / Fatty acid ester / Piperidinone / Fatty acyl / Piperidine / Tertiary carboxylic acid amide
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
fatty acid ester, naphthalenes, piperidones (CHEBI:40482)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated ...
Gene Name
ITGAL
Uniprot ID
P20701
Uniprot Name
Integrin alpha-L
Molecular Weight
128768.495 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:20